NCT01442090View on ClinicalTrials.gov

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

85

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2015

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Everolimus

Everolimus will be administered orally at a 10 mg daily dose.

DRUG

GDC-0980

GDC-0980 will be administered orally at a 40 mg daily dose.

Trial Locations (22)

10065

New York

10117

Berlin

27710

Durham

28041

Madrid

30625

Hanover

33075

Bordeaux

33705

St. Petersburg

33908

Fort Myers

37203

Nashville

44195

Cleveland

75908

Paris

81377

München

89148

Las Vegas

94800

Villejuif

02215

Boston

08003

Barcelona

08035

Barcelona

LS9 7TF

Leeds

EC1A 7BE

London

SW3 6JJ

London

M20 4BX

Manchester

SM2 5PT

Sutton

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY